{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Luque AE"],"funding":["NCATS NIH HHS","NCRR NIH HHS","NIAID NIH HHS"],"pagination":["2094-101"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4356823"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["59(4)"],"pubmed_abstract":["We conducted an open-label, steady-state pharmacokinetic (PK) study of drug-drug interactions between depot medroxyprogesterone acetate (DMPA) and twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV) (LPV/r) among 24 HIV-infected women and compared the results to those for HIV-infected women receiving DMPA while on no antiretroviral therapy or on nucleosides only (n = 14 subjects from the control arm of AIDS Clinical Trials Group [ACTG] study 5093). The objectives of the study were to address the effect of LPV/r on DMPA and to address the effect of DMPA on LPV/r therapy. PK parameters were estimated using noncompartmental analysis with between-group comparisons of medroxyprogesterone acetate (MPA) PKs and within-subject comparisons of LPV and RTV PKs before and 4 weeks after DMPA dosi"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study."],"pmcid":["PMC4356823"],"funding_grant_id":["UM1 AI069423","P30 AI050410","AI068634","UL1 TR000150","UM1 AI068632","UM1AI068616","UM1 AI106716","U01 AI069481","UM1 AI068634","UM1AI068636","UM1 AI068636","UM1AI106716","1U01AI068636","UM1 AI068616","UM1AI068632","UL1TR000150","U01 AI068636","UL-1RR02460","UM1 AI069481","1U01AI069481","UM1 AI106701","UM1 AI069511","P30 AI50410","U01 AI069471","UL1 TR002489","P30 AI027763","UL1 TR001111","1U01AI069513","1U01AI069511","1U01AI069471","1UL1TR001111","UM1 AI069471","UM1-AI069423-08","UM1 AI069496","U01 AI069511","U01 AI069513"],"pubmed_authors":["Weinberg A","Klingman KL","Park JG","Livingston E","Cohn SE","Watts DH","Luque AE","Cramer Y","Aweeka F"],"additional_accession":[]},"is_claimable":false,"name":"Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.","description":"We conducted an open-label, steady-state pharmacokinetic (PK) study of drug-drug interactions between depot medroxyprogesterone acetate (DMPA) and twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV) (LPV/r) among 24 HIV-infected women and compared the results to those for HIV-infected women receiving DMPA while on no antiretroviral therapy or on nucleosides only (n = 14 subjects from the control arm of AIDS Clinical Trials Group [ACTG] study 5093). The objectives of the study were to address the effect of LPV/r on DMPA and to address the effect of DMPA on LPV/r therapy. PK parameters were estimated using noncompartmental analysis with between-group comparisons of medroxyprogesterone acetate (MPA) PKs and within-subject comparisons of LPV and RTV PKs before and 4 weeks after DMPA dosi","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Apr","modification":"2025-04-04T19:19:57.216Z","creation":"2019-03-27T01:48:02Z"},"accession":"S-EPMC4356823","cross_references":{"pubmed":["25624326"],"doi":["10.1128/AAC.04701-14","10.1128/aac.04701-14"]}}